Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.
Status:
Not yet recruiting
Trial end date:
2035-05-02
Target enrollment:
Participant gender:
Summary
The purpose of the Columbus-AD study is to evaluate the efficacy and safety of 12 months of
encorafenib in combination with binimetinib in adjuvant setting of BRAF V600E/K mutant stage
IIB/C melanoma versus the current standard of care (surveillance).
Phase:
Phase 3
Details
Lead Sponsor:
Pierre Fabre Medicament
Collaborator:
European Organisation for Research and Treatment of Cancer - EORTC